Stock 300878 ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Wecome Pharmaceutical Company Limited

Equities

300878

CNE1000047P9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
15.07 CNY +2.87% Intraday chart for Zhejiang Wecome Pharmaceutical Company Limited -7.83% -40.60%
May. 22 Zhejiang Wecome Pharmaceutical Company Limited Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024 CI
Apr. 28 Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023
Capitalization 1 4,045 4,246 3,591 3,673
Enterprise Value (EV) 1 3,465 4,047 3,747 3,533
P/E ratio 24.8 x 44 x 80 x -423 x
Yield 1.99% 1.02% - 0.99%
Capitalization / Revenue 6.5 x 6.71 x 6.76 x 7.07 x
EV / Revenue 5.56 x 6.39 x 7.05 x 6.8 x
EV / EBITDA 25,676,927 x 41,467,293 x 57,976,027 x 258,348,036 x
EV / FCF -23.8 x -13.3 x -10.5 x 11.1 x
FCF Yield -4.2% -7.53% -9.55% 9.02%
Price to Book 2.93 x 3.04 x 2.57 x 2.64 x
Nbr of stocks (in thousands) 144,790 144,790 144,790 144,790
Reference price 2 27.94 29.32 24.80 25.37
Announcement Date 3/30/21 4/28/22 4/27/23 4/28/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 577.7 641.8 622.8 633 531.3 519.6
EBITDA - 135.4 134.9 97.6 64.63 13.67
EBIT 1 94.69 127.9 122.8 83.62 33.78 -20.29
Operating Margin 16.39% 19.92% 19.72% 13.21% 6.36% -3.91%
Earnings before Tax (EBT) 1 103.4 147.6 158.7 100 57.75 -5.786
Net income 1 87.78 126 135.8 96.5 44.44 -8.039
Net margin 15.2% 19.63% 21.81% 15.25% 8.37% -1.55%
EPS 2 0.8056 1.161 1.128 0.6667 0.3100 -0.0600
Free Cash Flow 1 -140.4 -58.32 -145.4 -304.9 -357.9 318.8
FCF margin -24.31% -9.09% -23.34% -48.18% -67.37% 61.35%
FCF Conversion (EBITDA) - - - - - 2,331.18%
FCF Conversion (Net income) - - - - - -
Dividend per Share - - 0.5556 0.3000 - 0.2500
Announcement Date 6/28/19 3/6/20 3/30/21 4/28/22 4/27/23 4/28/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - 4.04 - - 156 -
Net Cash position 1 13 - 581 198 - 140
Leverage (Debt/EBITDA) - 0.0299 x - - 2.419 x -
Free Cash Flow 1 -140 -58.3 -145 -305 -358 319
ROE (net income / shareholders' equity) 25.1% 27.6% 14.3% 6.91% 3.2% -0.44%
ROA (Net income/ Total Assets) 10.6% 10.5% 6.13% 3.15% 1.17% -0.64%
Assets 1 831.2 1,196 2,216 3,067 3,797 1,255
Book Value Per Share 2 3.630 4.790 9.540 9.650 9.660 9.600
Cash Flow per Share 2 0.7700 1.480 4.110 1.940 1.120 2.280
Capex 1 173 115 152 171 248 139
Capex / Sales 29.9% 17.91% 24.46% 27.03% 46.76% 26.81%
Announcement Date 6/28/19 3/6/20 3/30/21 4/28/22 4/27/23 4/28/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED Stock Zhejiang Wecome Pharmaceutical Company Limited
-40.60% 295M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+47.06% 765B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.74% 354B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.14% 331B
ABBVIE INC. Stock AbbVie Inc.
+8.78% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+18.87% 248B
ROCHE HOLDING AG Stock Roche Holding AG
-1.96% 219B
NOVARTIS AG Stock Novartis AG
+10.92% 216B
AMGEN INC. Stock Amgen Inc.
+4.87% 164B
PFIZER, INC. Stock Pfizer, Inc.
-2.71% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 300878 Stock
  4. Financials Zhejiang Wecome Pharmaceutical Company Limited